Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains treatment refractory. Immunotherapy has achieved success in the treatment of multiple malignancies. However, the efficacy of immunotherapy in PDAC is limited by a lack of promising biomarkers. In this research, we aimed to identify robust i...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ruiyu, He, Yangzhige, Zhang, Hui, Wang, Jing, Liu, Xiaoding, Liu, Hangqi, Wu, Huanwen, Liang, Zhiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320597/
https://www.ncbi.nlm.nih.gov/pubmed/34335594
http://dx.doi.org/10.3389/fimmu.2021.690056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320597/
https://www.ncbi.nlm.nih.gov/pubmed/34335594
http://dx.doi.org/10.3389/fimmu.2021.690056

Ejemplares similares